Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;23(6):417.
doi: 10.3892/mmr.2021.12056. Epub 2021 Apr 13.

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

Affiliations
Review

Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review)

Yi Zhang et al. Mol Med Rep. 2021 Jun.

Abstract

Spinal cord injury (SCI) is one of the most debilitating of all the traumatic conditions that afflict individuals. For a number of years, extensive studies have been conducted to clarify the molecular mechanisms of SCI. Experimental and clinical studies have indicated that two phases, primary damage and secondary damage, are involved in SCI. The initial mechanical damage is caused by local impairment of the spinal cord. In addition, the fundamental mechanisms are associated with hyperflexion, hyperextension, axial loading and rotation. By contrast, secondary injury mechanisms are led by systemic and cellular factors, which may also be initiated by the primary injury. Although significant advances in supportive care have improved clinical outcomes in recent years, a number of studies continue to explore specific pharmacological therapies to minimize SCI. The present review summarized some important pathophysiologic mechanisms that are involved in SCI and focused on several pharmacological and non‑pharmacological therapies, which have either been previously investigated or have a potential in the management of this debilitating injury in the near future.

Keywords: spinal cord injury; primary and secondary damage; systemic factors; local vascular effects; cyclooxygenase inhibitors; minocycline.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Pathophysiology of primary and secondary injury during spinal cord injury.
Figure 2.
Figure 2.
Different type of pharmacological drugs used for the treatment of SCI. SCI, spinal cord injury; FGF, fibroblast growth factor; a, acidic; b, basic.
Figure 3.
Figure 3.
Non-pharmacological therapies for the treatment of SCI. SCI, spinal cord injury.

References

    1. Hamid R, Averbeck MA, Chiang H, Garcia A, Al Mousa RT, Oh SJ, Patel A, Plata M, Del Popolo G. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36:1517–1527. doi: 10.1007/s00345-018-2301-z. - DOI - PubMed
    1. Hu HZ, Granger N, Jeffery ND. Pathophysiology, clinical importance, and management of neurogenic lower urinary tract dysfunction caused by suprasacral spinal cord injury. J Vet Intern Med. 2016;30:1575–1588. doi: 10.1111/jvim.14557. - DOI - PMC - PubMed
    1. Elliott CS, Dallas KB, Zlatev D, Comiter CV, Crew J, Shem K. Volitional voiding of the bladder after spinal cord injury: Validation of bilateral lower extremity motor Function as a key predictor. J Urol. 2018;200:154–160. doi: 10.1016/j.juro.2018.02.064. - DOI - PubMed
    1. Sharma HS. Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: Novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection. J Neural Transm (Vienna) 2011;118:155–176. doi: 10.1007/s00702-010-0514-4. - DOI - PubMed
    1. Tator CH. Experimental and clinical studies of the pathophysiology and management of acute spinal cord injury. J Spinal Cord Med. 1996;19:206–214. doi: 10.1080/10790268.1996.11719436. - DOI - PubMed

MeSH terms